肺癌免疫治疗年度进展2024  

Research progress in immunotherapy for lung cancer in 2024

作　　者：周晴 王孟昭[1] Zhou Qing;Wang Mengzhao(Department of Pulmonary and Critical Care Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医院呼吸与危重症医学科,北京100730

出　　处：《国际呼吸杂志》2025年第2期105-113,共9页International Journal of Respiration

基　　金：中央高水平医院临床科研专项(2022-PUMCH-B-106、2022-PUMCH-C-054)。

摘　　要：肺癌是国内发病率和病死率最高的癌症。近年来,以程序性死亡受体1/程序性死亡受体配体1单克隆抗体为代表的诸多免疫治疗药物蓬勃发展。免疫疗法因其良好的安全性、持久的治疗反应,以及对广大患者群体的有效性,深刻改变了肺癌的治疗格局。本文介绍了2024年非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)免疫治疗领域的研究进展。在NSCLC领域,围手术期免疫治疗模式改变了早期NSCLC的治疗格局;免疫治疗联合抗体偶联药物、双特异性抗体等新药有望进一步提高晚期NSCLC疗效。在SCLC领域,同步放化疗后免疫巩固治疗成为局限期SCLC治疗的新标准;广泛期SCLC治疗中联合抗血管药物等可能进一步提高患者生存,新型免疫药物研发亦不断涌现。Lung cancer is the leading cause of cancer incidence and mortality in China.Recently,with the emergence of immunotherapy drugs represented by programmed death-1/programmed death-ligand 1 monoclonal antibodies,immunotherapy is profoundly altering the cancer therapy owing to its less toxicity,sustained therapeutic response due to immunological memory generation,and effectiveness across a broad patient population.This article introduces the research progress in the field of immunotherapy for non-small cell lung cancer(NSCLC)and small cell lung cancer(SCLC)in 2024.The perioperative immunotherapy changed the treatment pattern of early-stage NSCLC.The combination of immune checkpoint inhibitors and other antitumor therapies such as antibody-drug conjugate and bispecific antibodies demonstrated favorable efficacy in advanced NSCLC.Consolidation immunotherapy after concurrent chemoradiotherapy has become a new standard care for patients with limited-stage SCLC.The addition of anti-angiogenic therapy and immune-checkpoint inhibition yielded improved overall survival in extensive-stage SCLC.Potential immune therapeutic targets were also explored.

关 键 词：癌 非小细胞肺 小细胞肺癌 免疫治疗 联合治疗 抗体偶联药物 抗血管治疗 

分 类 号：R73[医药卫生—肿瘤]